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From June 1996 until December 2007 we performed a two-step IRT/DNA-screening
for cystic ﬁbrosis for the eastern Part of Saxony in Germany. We screened 160,674
neonates and detected 38 cases of cystic ﬁbrosis.
Of those 38 patients with cystic ﬁbrosis 36 were followed up in our cystic ﬁbrosis
center until now. In comparison of those patients with age-correlated patients from
the German register we could show, that the frequence of cftr-mutations in our
population differes signiﬁcant in comparison to Germany. The age at diagnosis
was − as expected − with in the middle 97 days signiﬁcant lower than in the
rest of Germany with 3.6 years. Patients in eastern Saxony seemed two have a
slightly better growth and weight gain and a better FEV1. The ﬁrst detection of
Pseudomonas aeruginosa by throat swab we found in mid range at the age of 23.9
month, the data from the German register showed a ﬁrst detection in the middle at
the age of 42 month, wich is signiﬁcant later. But even so we found Pseudomonas
aeruginosa earlier in life, when we looked at the microbiological ﬁndings over the
years, we could show that in our screened population even so more microbiological
diagnostic per patient, visit and year was done than in the German population, we
had less Pseudomonas aeruginosa ﬁndings.
In Conclusion because auf the small number of patients, we couldn’t show sta-
tistical signiﬁcance of our ﬁndings, but we could show trends for a better weight
gain, growth and lung function and less pseudomonas-acquisition in the screened
population, wich should be a trend for implementation of a nationwide newborn
screening for cystic ﬁbrosis in Germany.
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The spectrum of presentation of cystic ﬁbrosis (CF) is wide and signiﬁcantly
varied. Neonatal hypertrypsinogenemia is one of the clinical symptoms due to
secretory abnormalities in pancreas. Neonatal screening for CF consists of the
immunoreactive trypsinogen (IRT) test at least as the ﬁrst step. The aim of the
investigation was to reveal the risk group of CF among newborns with the ﬁrst
positive IRT test result. DNA samples extracted from dried blood spots of 810
newborns with the ﬁrst positive IRT test result were analysed for 10 CFTR
mutations (CFTRdele2,3(21kb), F508del, Idel507, 1677delTA, 2184insA, 2143delT,
2183AA>G, 394delTT, 3821delT, L138insA). All newborns were from Moscow
and were born during 01.01.2008 to 31.12.2008 period. Screened mutations shared
for 67.5% of mutant alleles of CF patients from Russia. MultiplexPCR and gel
electrophoresis were carried out for mutation screening. 5 persons with two CFTR
mutations (3 − F508del/F508del, 1 − CFTRdele2,3(21kb)/CFTRdele2,3(21kb), 1 −
F508del/2184insA) and 33 persons with one mutant CFTR allele (26 heterozygous
for F508del, 4 − CFTRdele2,3(21kb), 1 − 3821delT, 1 − L138ins) were revealed
during the investigation. The total frequency of identiﬁed CF mutant alleles in
newborns with the ﬁrst positive IRT test result was 0.02654 (0.02031–0.03441)
in Moscow population. This evaluation is signiﬁcantly higher than the frequency
of these mutations in the sample of healthy individuals from Russian population
(0.00642 (0.0041–0.00951; p< 0.01).
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In Octobre NBSCF was added to routine newborn screening in Czech Republic. The
Brno CF centre being responsible for 40% of the Czech population (over 40,000
births a year). Each sample screening starts with quantiﬁcation of immunoreactive
trypsinogen (IRT) as 1st tier in dry blood. The test was considered positive
with concentration of IRT 65ml/l. For 2nd tier samples with elevated IRT are
analyzed for 36/32 CF mutations using INNO-LiPA CFTR19 + INNO-LiPA17+Tn
INNOGENETICS or ELUCINOGENETM CF-EU1 kits. Tests are positive when
2 CF mutations are identiﬁed. If 1 mutation is detected, sweat testing and second
IRT is performed to distinguish carriers from compound heterozygotes with second
CF mutation not identiﬁed on mutation screening panel. CF infants and their
families follow-up specialized medical care and genetic counseling. We have
obtained ﬁrst data of NBSCF. We have estimated provisionally frequency of CF in
NBSCF and carrier frequency: 1% newborns with IRT level over cut-off, 0.028%
newborns with conﬁrmed CF, 0.085% newborns CF carriers, 0.23% newborns with
polymorphisms with not conclusively clinical signiﬁcance, 0.06% newborns with
mild genotypes. We expect important information about the feasibility and reliability
of biochemically based NBSCF in comparison to a DNA based screening. Newborn
screening in our region is still in the early stages but has already presented many
beneﬁts: early diagnosis and prompt treatment, diagnosing CF among older siblings
and determination of CF carrier status in newborns and extended family members,
recognition of CF epidemiology and heterogeneity of CFTR mutations in Czech
Republic.
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We started a newborn screening (NS) for CF from September 1999 to 2008. 713422
newborns were screened. Our NS is based on determinations of IRT in the blood
spot collected at 3−5 days. Infants with higher cut-off (120 ng/ml) were recalled for
a second measurement (before 40 days of life). If the level remained high (cut-off
60 ng/ml) they were submitted to CFTR gene analysis (32 common mutations) and
to sweat testing. Newborns presenting one CF mutation and positive sweat test were
analysed for the complete CFTR gene (DGGE, SSCP and sequencing of abnormal
patterns).
Results: The IRT-1 was positive in 13.421 (1.8%) and the IRT-2 in 4.142 (0.5%).
The total number of CF patients identiﬁed by NS was 98. 42 CF patients were
identiﬁed by positive sweat test and two CF mutations in the ﬁrst gene analysis. 50
CF patients were diagnosed by second mutations identiﬁed by the complete CFTR
gene analysed. 6 patients were diagnosed by positive sweat test, and 2 mutations
in the complete CFTR gene. There were 5 false-negative cases and 24 cases with
inconclusive diagnosis. A total of 122 cases of CF (included 16 Meconium ileus
and 2 cases diagnosis by positive familiar history) were detected with an incidence
of 1/5.847 live births being much lower than the expected. F508del was found in
51% of alleles. Vit E levels were low in 47% of cases. No CF patients with chronic
colonisation of Pseudomonas aeruginosa were reported.
Conclusions: The NS for CF allowed assessing the incidence of CF in our
populations. The early diagnosis and treatment dramatically decrease the chronic
colonisation of Pa. Also declining CF birth rates as genetic screening effect must
be considered in future.
